Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24987101 | 1.00 | CFTR (0.37) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23905656 | 0.91 | CFTR (0.37) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL24987997 | 0.89 | GRM2 (0.37) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL31412429 | 0.89 | GRM2 (0.37) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23196094 | 0.89 | GRM2 (0.37) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23905474 | 0.88 | CFTR (0.35) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23904728 | 0.88 | CFTR (0.35) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23905836 | 0.86 | GRM2 (0.35) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL23905373 | 0.86 | GRM2 (0.35) | CFTRGRM2RORCPDE3BPDE3A | |
| SCHEMBL24984865 | 0.86 | CFTR (0.38) | CFTRGRM2RORCPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022086840-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | CFTR 307/4885GRM2 4418/4885RORC 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.